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Device Therapy
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Has CRT Changed
“the Sickest Benefit the Most”
to “the Healthiest Benefit the Most?”*
Maurizio Gasparini, MD, Paola Galimberti, MD
Rozzano-Milan, Italy
In this issue of the Journal, Kutyifa et al. (1) present interesting
and intriguing results derived from a post hoc analysis of the
MADIT-CRT (Multicenter Automatic Defibrillator Implan-
tation Trial With Cardiac Resynchronization Therapy) study.
The correlation between baseline left ventricular ejection frac-
tion (LVEF) and outcome after cardiac resynchronization
therapy (CRT) was analyzed by dividing patients into 3 groups
according to baseline LVEF:30%, 26% to 30%, and25%.
The authors focused particularly on patients who, after an echo
core laboratory re-evaluation, were found to have a baseline
LVEF 30%, which was beyond the stated eligibility criteria
f the MADIT-CRT trial.
See page 936
Reverse remodeling and outcome were significantly better
in patients with baseline LVEF30% (1). In fact, the mean
reduction in left ventricular end-diastolic volume with
CRT, as well as reduction in hospitalization/deaths after
CRT, was directly related to increasing LVEF. The paper is
notable because these unequivocal results derived from such
a large, prospective, multicenter trial (more than 1,800
patients with mild heart failure [HF]) could well lead
guideline administrators to expand CRT indications. In
addition to the general appreciation of this work, there are
some major points that need to be discussed.
First, the main message of the paper is that in the mild
HF population, patients with lower LVEF derive signifi-
cantly less benefit from CRT in terms of reverse remodeling
and HF hospitalizations with respect to patients with higher
LVEF. Conversely, patients with somewhat better LVEF
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
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Center, Rozzano-Milano, Italy. Both authors have reported that they have no
relationships relevant to the contents of this paper to disclose.(in the range of 30% to 35%) may well be the best
responders. Second, the widely accepted concept of the
relevance of dyssynchrony to predict CRT response is
contradicted by these data; in fact, in this large population
affected with mild HF, the higher grade of dyssynchrony
was inversely correlated with CRT response. Lastly, base-
line “local” echocardiograms were re-analyzed by a central-
ized echo core laboratory that had not been used during the
original study. The large percentage (38%) of patients with
LVEF 30% (and therefore beyond the eligibility criteria)
is a surprising but highly important finding. In addition, in
some cases, there was remarkable discrepancy between local
and centralized echo evaluation (enrolling patients re-
evaluated with LVEF, 45%). This point truly questions the
accuracy of baseline LVEF evaluation in the absence of
centralized data collection and evaluation.
Patient selection in CRT and adequate follow-up: the
“sweet spot” for CRT. Approximately one-third of CRT
recipients fitting current CRT guidelines do not improve
with this therapy. Conversely, once a therapy has been
demonstrated to be effective in a selected population,
obtaining striking results, clinical practice may drift away
from evidence determined on the basis of clinical trials and
try to extend these advantages to the largest portion of the
HF population that could potentially benefit from such
therapy.
From this perspective, there has been a meaningful
evolution of CRT candidates over the years (Fig. 1). In the
first era of CRT, patients with HF were enrolled in phase A
(i.e., CRT as a “last-resort therapy”: at an advanced stage of
the disease with significantly, and probably excessive, com-
promised left ventricular [LV] function). The hemodynamic
“switch on/off” effect of CRT was evidently documented
during hemodynamic acute studies (2,3), as well as in
studies evaluating the acute effects of CRT on dyssyn-
chrony. This kind of “the miraculous switch off-switch on
effect” permitting the dramatic amelioration of volume-
pressure curves and demonstration of unquestionably sig-
nificant gains in systolic blood pressure, excited electro-
physiologists and HF physicians. However, most of those
compromised patients, unequivocally “responders” in the
acute phase, nonetheless showed poor outcome at mid- to
long-term follow-up. As long as the different CRT trials
enrolled less-compromised patients, aiming to detect gain in
reverse remodeling and mortality, a continuum of progres-
sive response became evident, and patient enrollment
shifted from phase A to B and C, with guidelines excluding
nonambulatory patients with New York Heart Association
(NYHA) class IV.
A preventive strategy has evolved, step by step, after the
REVERSE (Resynchronization Reverses Remodeling in Sys-
tolic Left Ventricular Dysfunction) trial (4), the MADIT-
RT study (5), and the RAFT (Resynchronization/
efibrillation in Ambulatory Heart Failure Trial) study (6),
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patients (Phases D and E in Fig. 1).
The paper by Kutyifa et al. (1) adds new and interesting
data supporting the notion that “moderately” compromised
LV systolic function (the “sweet spot,” as described by the
authors) may be associated with the greatest benefits from
CRT. Moreover, these data confirmed our previous finding
on HF remission observed after CRT (7). We sought to
determine whether CRT induces an HF remission (NYHA
I; LVEF 50%) and to define the incidence and predictors
of such a process. At multivariable analysis, nonischemic
etiology, LVEF 30% to 35%, and left ventricular end-
diastolic volume180 ml were strongly associated with HF
recovery.
The natural course of device therapy in HF, and partic-
ularly the paper by Kutyifa et al. (1), in part contradict the
old and well-known concept that “the sickest patients
benefit the most” (8).
However, it is not really surprising that, at the beginning
of device therapy in HF (when only simple implantable
cardioverter-defibrillators [ICDs] were used), the best can-
didates and responders were “the sickest.” In these patients,
use of the ICD led to a remarkable lowering of total
mortality at short-term follow-up. With CRT in addition to
ICD, the scenario has changed completely: from a very
compromised HF patient saved only from sudden death
(but subsequently dying of refractory HF), to a less-
compromised HF patient saved from both sudden and HF
death.
Conversely, less-compromised patients (with a lower
baseline mortality rate and lower LV dysfunction) (5–7)
obviously need a much longer follow-up to show CRT
benefit, in terms of reverse remodeling and significant
reduction of HF hospitalizations and total mortality. In
Figure 1 Comparison of Theoretical CRT Response According
to Baseline LVEF, NYHA Class, DYSS, and EDV
CRT  cardiac resynchronization therapy; DYSS  dyssynchrony; EDV  end-
diastolic volume; f.u.  follow-up; LVEF  left ventricular ejection fraction;
NYHA  New York Heart Association.these cases, the “miraculous switch-on effect” of CRT is pprobably difficult (if not impossible) to observe, and a much
longer follow-up is likely needed to demonstrate significant
effects on hard endpoints.
The concept of needing a much longer time to demon-
strate mortality reduction has been indeed confirmed by
Kutyifa et al. (1), who explained that this too short
follow-up may be the reason why “CRT-D was not associ-
ated with a statistically significant effect on the risk of
all-cause mortality.”
Of note, at baseline, the 3 groups presented significantly
different end-diastolic volume (EDV) (being larger in
LVEF 25%, as expected), and the EDV reduction ob-
served after 12 months of CRT was significantly larger in
patients with higher LVEF. Thus, at 1-year follow-up, the
EDV differences became even more pronounced in the 3
groups (a mean of 123 indexed ml vs. 100 ml vs. 88 ml,
respectively). Looking at such large discrepancies in LV
volumes, it is possible that patients with higher baseline
LVEF, presenting dramatically smaller EDV after 12
months of CRT, might show lower mortality rates at
long-term follow-up.
Dyssynchrony and CRT. Until now, “the higher the
dyssynchrony, the better the results from CRT” has been
considered a paradigmatic concept. However, despite hun-
dreds of studies stating that dyssynchrony identified by
using echocardiography is a fundamental prerequisite for
the success of CRT, no single predictive and reproducible
dyssynchrony parameter has been confirmed as useful in
randomized trials (3). Consequently, no single dyssyn-
chrony criterion is included in recent guidelines (9).
Kutyifa et al. (1) now present extremely interesting data
that simply contradict the “leitmotiv” concept that the
higher the degree of LV dyssynchrony, the greater the
response to CRT. From the data of the MADIT-CRT
study, it seems reasonable to conclude that dyssynchrony
seems to be correlated to large baseline LV volumes and low
LVEF. More important, extreme degrees of dyssynchrony
seem to be inversely correlated to CRT response, at least in
patients with mild HF.
Did the MADIT-CRT LVEF criteria “truncate” patients
ho could benefit? These new data from Kutyifa et al. (1)
eads one to wonder about some important global implica-
ions of the MADIT-CRT results. The trial aimed at
ecruiting patients with LVEF 30%. Now, the echo core
aboratory re-evaluation shows that many (38%) of the
nrolled patients had LVEF 30%. This finding leads to 2
uestions: 1) What would have been the results of MADIT-
RT if indeed the patients had all had LVEF 30%? 2)
ad MADIT-CRT used the LVEF 35% criterion, al-
eady accepted for CRT indications by guidelines, how
uch larger a patient population would have been addressed
y the trial and, consequently, would now be considered
ood candidates for CRT-D therapy?
In terms of the first question, because the study by
utyifa et al. (1) clearly showed that the best results were in
atients with mild HF with LVEF 30%, this finding can
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CRT would have been less positive (because many of the
atients with the better results would not have been
ncluded.) To be perfectly clear, we have no grounds to
uggest that the dramatic positive results of MADIT-
RT would have become negative or neutral; simply,
here is a strong probability that they would have been
omewhat less positive. In this regard, we must remember
hat both REVERSE (4) and RAFT (6), with similar
atient populations (and LVEFs), also showed beneficial
utcome for patients with mild HF treated with CRT.
However, perhaps the second question (What if the
nclusion criteria had used the “natural” limit of LVEF
35%?) has even more important clinical consequences.
ere, we may legitimately speculate that even more positive
esults (driven by patients with higher LVEF) would have
een obtained if the enrollment criteria had included pa-
ients with LVEF of 30% to 35%. A clear message would
hen be reported by guidelines ¡ NYHA II-ambulatory IV
F patients on OPT with QRS >120-130 ms and EF
35% should be eligible for CRT.
In the recent ESC CRT guidelines (9), prevalent up to
he update decided literally in the past days (10), NYHA II
atients with an LVEF of 30% to 35% had been excluded.
onsequently, probably the best responders to CRT were in
his “limbo” until guidelines committees took these new and
mportant data into consideration. Taking into account the
ust-published 2012 AHA Focused Updated Guidelines for
evice-Based Therapy of Cardiac Rhythm Abnormalities
10), patients with HF with LVEF 35% and NYHA class
I are now considered as class I, level B in the presence of
eft bundle branch block and QRS duration 150 ms. This
mportant decision is following the concept of a more
preventive therapy” for CRT in this population. Thus, the
isk of leaving out patients with LVEF 30% to 35%, who are
robably the best responders to CRT and who, per previous
uidelines, had unfortunately been left “in limbo” (9), has
een dramatically reduced.
onclusions. Red traffic lights are still present, but the
irection seems correct and the reverse path is from “the
ickest patients benefit the most” to “the healthiest patients
enefit the most.”Reprint requests and correspondence: Dr. Maurizio Gasparini,
Humanitas Clinical and Research Center, Electrophysiology and
Pacing Unit, Via Manzoni, 56, Rozzano (MI) 20089, Italy.
E-mail: maurizio.gasparini@humanitas.it.
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